TL
Therapeutic Areas
Liquidia Pipeline
| Drug | Indication | Phase |
|---|---|---|
| YUTREPIA™ (treprostinil) inhalation powder | Pulmonary Arterial Hypertension (PAH) | Approved |
| LIQ861 (treprostinil) inhalation powder | Pulmonary Arterial Hypertension (PAH) | Phase 3 |
| L606 (liposomal treprostinil) injection | Pulmonary Arterial Hypertension (PAH) | Preclinical |
Leadership Team at Liquidia
RA
Roger A. Jeffs, Ph.D.
President and Chief Executive Officer
MK
Michael Kaseta
Chief Financial Officer and Treasurer
TS
Tushar Shah, M.D.
Chief Medical Officer
MD
Michael D. Jaffee
Chief Commercial Officer
SB
Steven B. Simonson, M.D.
Senior Vice President, Clinical Development
DL
David L. Tome
Senior Vice President, Operations and Supply Chain
PB
Paul B. Manning
Chairman of the Board